Gabalex Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Gabalex Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,000	Closed	-$3.79M	–	22
2021 Q1	$3.79M	Sell	60,000 -10,541	-15%	-$656K	1.91%	20
2020 Q4	$4.38M	Sell	70,541 -129,459	-65%	-$7.96M	2.37%	17
2020 Q3	$12.1M	Hold	200,000	–	–	3.37%	14
2020 Q2	$11.8M	Sell	200,000 -25,000	-11%	-$1.5M	3.7%	12
2020 Q1	$12.5M	Buy	225,000 +25,000	+13%	+$1.53M	4.32%	10
2019 Q4	$12.8M	Hold	200,000	–	–	3.36%	15
2019 Q3	$10.1M	Buy	200,000 +50,000	+33%	+$2.35M	2.74%	16
2019 Q2	$6.8M	Buy	150,000 +25,000	+20%	+$1.16M	1.77%	17
2019 Q1	$5.96M	Buy	+125,000	New	+$6.23M	1.72%	17

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Gabalex Capital Management's BMY Position: Q2 2021 in Review

Gabalex Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 60,000 shares — an estimated $3.79M sold.

Gabalex Capital Management first reported a position in BMY in Q1 2019 and held it in 9 quarters. The position peaked at $12.8M in Q4 2019. 2,370 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

Gabalex Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
Gabalex Capital Management sold 60,000 Bristol-Myers Squibb shares in Q2 2021, an estimated $3.79M.
Gabalex Capital Management first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 9 quarters.
Gabalex Capital Management's Bristol-Myers Squibb position peaked at $12.8M in Q4 2019.
2,370 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on Gabalex Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.